abstract the present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4- [(3s, 3ar) -3-cyclopentyl-7- (4-hydroxypiperidin-1-carbonyl) -3,3a, 4,5-tetrahydro-2h-pyrazolo [3,4-f] quinolin-2-yl] benzonitrile of formula (1)； a crystal form thereof, the preparation method for the crystal form, and the use of the crystal form in the preparation of drugs for the treatment and / or prevention of renal injury or cardiovascular diseases. Formula (1) ______________________________________________________________ patent summary: "crystalline form of the compound used as a mineralocorticoid receptor antagonist and method for its preparation". The present invention belongs to the technical field of medicaments, and relates to a crystalline form of a compound used as a mineralocorticoid receptor antagonist and a method for its preparation, and in particular to a method for the preparation of a compound. 2-chloro-4 - [(3s, 3ar) -3-cyclopentyl-7- (4-hydroxypiperidine-1-carbonyl) -3,3a, 4,5-tetrahydro-2h-pyrazol [3,4-f] quinoline -2-yl] benzonitrile of formula (I), a crystalline form thereof, a method of preparation for the crystalline form, and the use of the crystalline form in the preparation of medicaments for the treatment and / or prevention of kidney injury or cardiovascular diseases.abstract the present invention belongs to the technical field of medicines, and relates to a crystal form of a compound used as a mineralocorticoid receptor antagonist and a preparation method therefor, and in particular, to a method for preparing a compound 2-chloro-4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidin-1-carbonyl)-3,3a,4,5-tetrahydro-2h-pyrazolo[3,4-f]quinolin-2-yl]benzonitrile of formula (1)； a crystal form thereof, a preparation method for the crystal form, and the use of the crystal form i
